COMMUNIQUÉS West-GlobeNewswire

Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025
07/05/2025
Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes in patients with wet AMD and DME Gräfelfing, Germany, May 7 th , 2025 – Isarna Therapeutics [...]
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025
Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of [...]
Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07/05/2025
REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
LifeStance Reports First Quarter 2025 Results
07/05/2025
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the first [...]
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
07/05/2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health [...]
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
07/05/2025
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases [...]
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
07/05/2025
Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales SYFOVRE ® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 [...]
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
07/05/2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 [...]
Lirum Therapeutics Announces New LX-101 Data in Thyroid Eye Disease Selected for Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
07/05/2025
New York, NY, May 07, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new [...]
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
07/05/2025
-- First quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI [...]
Castle Biosciences Celebrates Skin Cancer Awareness Month
07/05/2025
The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor [...]
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
07/05/2025
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, [...]
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07/05/2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ g, Including One [...]
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
07/05/2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Valneva publie ses résultats financiers du premier trimestre 2025 et fait un point sur son activité
07/05/2025
Chiffre d’affaires de 49,2 millions d’euros contre 32,8 millions d’euros au premier trimestre 2024 Trésorerie et équivalents de trésorerie de 153,0 millions d’euros à fin mars 2025 Poursuite des avancées cliniques et [...]
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07/05/2025
Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024 Cash and cash equivalents of €153.0 million at end of March 2025 Further clinical and regulatory progress 2025 financial outlook [...]
CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
07/05/2025
Communiqué de presse CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE® CROSSJECT et son partenaire EUROFINS ont achevé avec succès le remplissage aseptique de tous les lots [...]
CROSSJECT provides updates on the EUA filing of ZEPIZURE®
07/05/2025
Press Release CROSSJECT provides updates on the EUA filing of ZEPIZURE® CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the [...]
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
07/05/2025
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% at constant exchange rates (CER) to DKK 38.8 billion. Sales in US Operations [...]

Pages